Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid tumors of the digestive tr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Drug Des Devel Ther
Prif Awduron: Wolin, Edward M, Jarzab, Barbara, Eriksson, Barbro, Walter, Thomas, Toumpanakis, Christos, Morse, Michael A, Tomassetti, Paola, Weber, Matthias M, Fogelman, David R, Ramage, John, Poon, Donald, Gadbaw, Brian, Li, Jiang, Pasieka, Janice L, Mahamat, Abakar, Swahn, Fredrik, Newell-Price, John, Mansoor, Wasat, Öberg, Kjell
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2015
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4562767/
https://ncbi.nlm.nih.gov/pubmed/26366058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S84177
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg